Daniel C Brennan
Overview
Explore the profile of Daniel C Brennan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
259
Citations
5676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaufman D, Akkina S, Stegall M, Piper J, Gaber A, Asch W, et al.
Am J Transplant
. 2025 Feb;
PMID: 39922283
This phase 3 multicenter, randomized, controlled clinical trial evaluated investigational cellular product (MDR-101) to produce immune tolerance vs standard of care, in kidney transplant recipients. Adult recipients of kidneys from...
2.
Salto-Alejandre S, Cochran W, Siddiqui Z, Langlee J, Boyer L, Freed K, et al.
Transpl Infect Dis
. 2024 Nov;
27(1):e14405.
PMID: 39549258
Background: Outcomes after bebtelovimab treatment for COVID-19 were favorable for most but not all solid organ transplant recipients (SOTRs) during the era of Omicron BA.2 to BA.5, but effects of...
3.
Maqsood R, Wu L, Brennan D, Lim E
Microbiol Spectr
. 2024 Jun;
12(8):e0405523.
PMID: 38916313
Importance: The urinary microbiome is increasingly implicated in renal health and disease. While most research focuses on bacteria communities of the microbiome, factors that influence the urinary virome are not...
4.
Crepeau P, Liu Y, Zhou Done J, Done J, Foote D, Brennan D, et al.
J Am Coll Surg
. 2024 Jun;
239(6):600-608.
PMID: 38895942
Background: Before kidney transplantation (KT), most patients have an elevated parathyroid hormone (PTH). However, the impact of PTH on post-KT mortality and graft loss is unclear. We quantified the association...
5.
Kotton C, Kamar N, Wojciechowski D, Eder M, Hopfer H, Randhawa P, et al.
Transplantation
. 2024 Apr;
108(9):1834-1866.
PMID: 38605438
BK polyomavirus (BKPyV) remains a significant challenge after kidney transplantation. International experts reviewed current evidence and updated recommendations according to Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). Risk factors...
6.
Hardinger K, Brennan D
Ann Pharmacother
. 2024 Mar;
58(11):1122-1133.
PMID: 38501850
Objective: The article reviews the safety and efficacy of treatments for cytomegalovirus (CMV) in solid organ transplantation. Data Sources: A literature review was conducted in PubMed, MEDLINE, and Clinicaltrials.gov from...
7.
Chan S, Cazzolli R, Jaure A, Johnson D, Hawley C, Craig J, et al.
Transplantation
. 2024 Feb;
108(3):588-592.
PMID: 38385339
No abstract available.
8.
Hladek M, Wilson D, Krasnansky K, McDaniel K, Shanbhag M, McAdams-DeMarco M, et al.
Kidney360
. 2024 Feb;
5(4):589-598.
PMID: 38379153
No abstract available.
9.
Seifert M, Mannon R, Nellore A, Young J, Wiseman A, Cohen D, et al.
Transpl Infect Dis
. 2024 Feb;
26(2):e14237.
PMID: 38341645
Background: BK polyomavirus (BKV) can cause permanent loss of allograft function due to BKV-associated nephropathy (BKVN) in kidney transplant recipients. Besides immunosuppression reduction, there are no consistently effective interventions for...
10.
Schenk K, Deutsch J, Chandra S, Davar D, Eroglu Z, Khushalani N, et al.
J Clin Oncol
. 2024 Jan;
42(9):1011-1020.
PMID: 38252910
Purpose: Cancer-related mortality rates among kidney transplant recipients (KTR) are high, but these patients have largely been excluded from trials of immune checkpoint inhibitors because of immunosuppression and risk of...